Covidien Ltd news

   Watch this stock
Showing stories 1 - 10 of about 88   

Articles published

COV 106.71 0.00 (0.00%)
price chart
Baxter Names Jose Almeida, Former Head of Covidien, New CEO
Almeida, a native Brazilian who goes by "Joe," took over as the second CEO of Covidien in 2011 after it was spun off from Tyco International Ltd. in 2007. He first joined the company as director of manufacturing in 1995 and rose to president of ...
Baxter names Jose Almeida, former head of Covidien, as new CEO  Chicago Daily Herald
Baxter appoints Jose Almeida chairman and CEO  PMLiVE
The Tax-Shopping Backstory of the Medtronic-Covidien Inversion
A new regime spun off Tyco's health care unit into a separate publicly traded firm, Covidien Ltd., also headquartered in Bermuda.
Medtronic to Buy Device Maker Covidien for $42.9 Billion  Bloomberg
Medtronic set to acquire rival medical device maker Covidien  Financial Times
Related articles »  
Covidien to Buy Jerusalem-Based Oridion for $346 Million
Covidien Plc agreed to buy Oridion Systems Ltd., an Israeli maker of devices for patient breathing safety, for $346 million.
Covidien acquires Oridion for $346m  Globes
PolyTouch Medical Acquired by Covidien
PolyTouch Medical Ltd., a leading developer of hernia mesh placement technologies, was acquired by Covidien (NYSE: COV), a leading global provider of healthcare products that is traded on the New York Stock Exchange at a current market value of $26 ...
Covidien Announces Definitive Agreement to Acquire Given Imaging
DUBLIN, Ireland & YOQNEAM, Israel--(BUSINESS WIRE)--Covidien plc (NYSE: COV) and Given Imaging Ltd. (Nasdaq: GIVN) today announced a definitive agreement under which Covidien will acquire all of the outstanding shares of Given Imaging for ...
Covidien buys Given Imaging for $860m  Globes
The Deal: Israel's Given Imaging Surges on $860 Million Covidien Buyout  TheStreet.com
Related articles »  
Medtronic Sales Beat Analysts' Estimates After Covidien Deal
While Medtronic previously reported sales by product category, including high-powered defibrillators, replacement heart valves, and spinal products, the company condensed the way it details its results after buying Covidien. ... “The smaller decline in ...
Moody's upgrades Covidien's long term rating to A3 from Baa1; outlook negative
New York, January 27, 2015 -- Moody's Investors Service today upgraded the senior unsecured debt ratings of Covidien International Finance SA to A3 from Baa1.
Medtronic: the tax inversion that got away  Financial Times
Medtronic Strategy Takes Shape After Biggest Inversion Ever  Bloomberg
Tissue Regenix May Attract Suitors After Covidien Deal
Ongoing clinical studies and initial sales of DermaPure over the next year or two could lead to Tissue Regenix becoming a takeover target, Martin Brunninger, an analyst at Jefferies International Ltd. in London, said in a note to investors on June 12 ...
Related articles »  
Medtronic Profit Beats Estimates After Covidien Purchase
In the quarter ended in April -- the first full period since the Covidien deal -- Medtronic had a profit of $1.16 a share, excluding one-time items, compared with the $1.12 average of estimates compiled by Bloomberg.
In Wake of Medtronic's Covidien Deal, Bernstein Asks: Who's Next?
Slower growth, pricing pressures and the overhaul of the U.S. health-care system are driving deals like Medtronic's Covidien takeover and other recent acquisitions, including Zimmer Holdings Inc.'s agreement in April to purchase Biomet Inc. for $13 ...
Medtronic Likely To Be Booted From Fortune 500 Over Deal To Move HQ Overseas  Twin Cities Business Magazine
Tax Inversions: Tail Wags Dog?  ValueWalk
Related articles »